The apelin-APJ axis in infantile hemangioma: Emerging evidence and potential links to propranolol response.
Chen Qiang Q, Chen Meng M, Chen Bin B, Xie Yimin Y
Propranolol is the standard first-line systemic therapy for infantile hemangioma (IH), but its antiangiogenic mechanisms remain incompletely defined. Emerging evidence implicates the apelin-APJ system in IH endothelial biology. APJ is enriched in hemangioma-derived endothelial cells (HemECs), and pharmacological inhibition suppresses proliferation, migration and angiogenic behavior, with genetic experiments supporting an APJ-dependent component. Separately, propranolol reduces APLN transcription in IH-derived models, and circulating apelin declines during treatment. These findings motivate investigation of an indirect link through ligand regulation, but do not establish APJ-dependent mediation of propranolol efficacy. This review distinguishes ligand transcription, ligand abundance, receptor expression and receptor-dependent function, integrating IH observations with mechanistic evidence from other vascular and disease models. We examine endothelial cell states, HIF-1α-dependent transcription, and the distinct SOX18-mevalonate mechanism of R(+)-propranolol. Cross-disease intervention studies provide a rationale for investigating treatment responsiveness. Priorities include defining functional ligand sources and recipient cells, testing receptor-dependent effects on drug response, validating circulating biomarkers, and establishing developmental safety before therapeutic translation.